Ohly Launches New Probiotic Yeast
25 Aug 2015 --- Following hard on the heels of a successful cGMP certification and their newly confirmed status as an authorised API manufacturer, Ohly has announced the release of Auxoferm Saccharomyces boulardii – a probiotic yeast that is set to transform the efficacy of oral rehydration systems for patients the world over. The latest release will have applications dependent on regional legislation that range from API to Food and Feed Supplements.
Fabienne Saadane-Oaks, CEO of the ABF Ingredients group of companies that includes Ohly says “Best practice goes hand-in-hand with tireless R&D. The certification demonstrates that strength perfectly while the launch of Auxoferm Saccharomyces boulardii enhances our portfolio and showcases the latest expression of our commitment to applications that deliver real benefits.”
Auxoferm Saccharomyces boulardii has unprecedented functionality as a yeast-based probiotic that balances the natural intestinal bacteria, while strengthening the immune system and restoring healthy bowel rhythm. The ingredient delivers relief and prevention for viral, bacterial and antibiotic-associated diarrhoea – a pernicious killer in many countries around the world. Auxoferm Saccharomyces boulardii is resistant to common antibiotics, fights the overgrowth of harmful bacteria and promotes the growth of intestinal microflora.
Key Benefits of Saccharomyces Boulardii:
• Helps improve digestion
• Helps treat all kinds of diarrhoea including antibiotic associated diarrhoea
• Helps treatment of Irritable Bowel Syndrome
• Supports gut function against food allergies, Crohn’s disease, Salmonella
• Reduces bloating and gas
• Lactose Free
• Gluten Free
• Suitable for vegetarian and vegan
Auxoferm Saccharomyces boulardii is manufactured through yeast fermentation, separation and a drying process that removes moisture from the yeast to permit room temperature storage and clinical efficacy.
